Keywords: Biosimilars, Development, Production, Catalent Pharma, UMN Pharma, Japan

Catalent and UMN Pharma collaborate for biosimilars development and production in Japan

Article | 16 December 2012

Privately-held USA-based Catalent Pharma Solutions and Japanese drugmaker UMN Pharma (TYO Mothers: 4585) have signed an agreement to provide UMN Pharma ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

UMN Pharma

Catalent Pharma Solutions

Go to company listing